Hepatic but not Intestinal FBP1 Is Required for Fructose Metabolism and Tolerance
Endocrinology · 17.04.2023 · 164 (6)
DOI: 10.1210/endocr/bqad054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, online erschienen am 25.03.2023. Verfasst von Qiufang Bai und 8 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of En…. Hauptthemen laut MEDLINE: Fructose, Fructose Intolerance. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Key Research and Development Program, National Natural Science Foundation of China, Collaborative Innovation Program of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Fructose intolerance in mammals is caused by defects in fructose absorption and metabolism. Fructose-1,6-bisphosphatase 1 (FBP1) is a key enzyme in gluconeogenesis, and its deficiency results in hypoglycemia as well as intolerance to fructose. However, the mechanism about fructose intolerance caused by FBP1 deficiency has not been fully elucidated. Here, we demonstrate that hepatic but not intestinal FBP1 is required for fructose metabolism and tolerance. We generated inducible knockout mouse models specifically lacking FBP1 in adult intestine or liver. Intestine-specific deletion of Fbp1 in adult mice does not compromise fructose tolerance, as evidenced by no significant body weight loss, food intake reduction, or morphological changes of the small intestine during 4 weeks of exposure to a high-fructose diet. By contrast, liver-specific deletion of Fbp1 in adult mice leads to fructose intolerance, as manifested by substantial weight loss, hepatomegaly, and liver injury after exposure to a high-fructose diet. Notably, the fructose metabolite fructose-1-phosphate is accumulated in FBP1-deficient liver after fructose challenge, which indicates a defect of fructolysis, probably due to competitive inhibition by fructose-1,6-bisphosphate and may account for the fructose intolerance. In conclusion, these data have clarified the essential role of hepatic but not intestinal FBP1 in fructose metabolism and tolerance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China.
- Department of Pathophysiology, Naval Medical University, Shanghai 200433, China.
ORCID-Profile: Ya-Nan Shi, Weiping J Zhang
Förderung
- National Key Research and Development Program
- National Natural Science Foundation of China
- Collaborative Innovation Program of Shanghai Municipal Health Commission
Zitieren
APA
Bai, Q., Liu, Y., Wang, C. M., Wang, J. R., Feng, Y., Ma, X., Yang, X., Shi, Y. N., & Zhang, W. J. (2023). Hepatic but not Intestinal FBP1 Is Required for Fructose Metabolism and Tolerance. Endocrinology, 164(6). https://doi.org/10.1210/endocr/bqad054
Vancouver
Bai Q, Liu Y, Wang CM, Wang JR, Feng Y, Ma X, et al. Hepatic but not Intestinal FBP1 Is Required for Fructose Metabolism and Tolerance. Endocrinology. 2023;164(6). doi:10.1210/endocr/bqad054
BibTeX
@article{Bai2023,
author = {Bai, Qiufang and Liu, Yajin and Wang, Chen-Ma and Wang, Jue-Rui and Feng, Yingying and Ma, Xianhua and Yang, Xiaohang and Shi, Ya-Nan and Zhang, Weiping J},
title = {Hepatic but not Intestinal FBP1 Is Required for Fructose Metabolism and Tolerance},
journal = {Endocrinology},
year = {2023},
volume = {164},
number = {6},
doi = {10.1210/endocr/bqad054}
}
EUVIMED